- Our Products & Expertise
- About Baxter
- Corporate Responsibility
- Contact & Support
It looks like your browser is outdated. For the best experience, please consider updating to the latest version or switching to another browser (Firefox, Chrome, Safari).
2015 was a pivotal year for Baxter: In July we executed the spinoff of our BioScience business. The corporate separation created value for investors and resulted in a Baxter portfolio focused solely on the Hospital Products and Renal technologies central to our core identity. Today we are collaborating around the world to shape a leaner, more efficient company, positioned to deliver on our mission and succeed on behalf of all our stakeholders well into the future.View our latest Annual Report
|Data provided by Nasdaq. Minimum 15 minutes delayed.|
Baxter International Inc. to Host First Quarter 2017 Financial Results Conference Call for Investors
Baxter and the Institute for Safe Medication Practices (ISMP) Address Global Medication Error Prevention
New Data Indicates Use of Baxter’s FLOSEAL in Cardiac and Spinal Surgeries May Be Associated with Lower Hospital Costs
Analysts, portfolio managers, and current and prospective shareholders seeking additional investor information can contact Clare Trachtman at +1 (224) 948-3085.
Retail shareholder inquires may directed to Baxter Investor Relations at Global_CORP_Investor_Relations@baxter.com.Sign up for email alerts